Investigational drug · Phase 2
NST-1024
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for High Triglycerides.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "NST-1024"
First trial start
2023
Jun 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NST-1024", any sponsor or status.
Conditions studied
As listed on its trial records.
- High Triglycerides
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NST-1024" as an intervention, largest first.
NorthSea Therapeutics B.V.Industry
NCT04630366 · 96 participants · Start Oct 27, 2020 · Primary completion Jun 20, 2022
Drug: NST-1024; Placebo · For: Hypertriglyceridemia
Sites: Leeds, United Kingdom
- Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With HypertriglyceridemiaCompleted
NorthSea Therapeutics B.V.Industry
NCT05889156 · 50 participants · Start Jun 30, 2023 · Primary completion Mar 18, 2025
Drug: NST-1024 · For: High Triglycerides
Sites: Birmingham, Alabama; Daphne, Alabama; Tempe, Arizona · 31 sites in all
- Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy SubjectsCompleted
NorthSea Therapeutics B.V.Industry
NCT05368831 · 24 participants · Start Jul 19, 2022 · Primary completion Sep 7, 2022
Drug: NST-1024 · For: Healthy Volunteers
Sites: Leeds, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- NST-1024 for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 28-day clinical trial.
Kastelein JJ, Skjæret T, Jeannin S, et al. · J Clin Lipidol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.